Beam Therapeutics Inc.
BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$21.90
Price-1.31%
-$0.29
1Y
Price
Market Cap
$2.231b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+228.4%
EBITDA Margin+214.1%
Net Profit Margin-76.3%
Free Cash Flow Margin+228.4%
EBITDA Margin+214.1%
Net Profit Margin-76.3%
Free Cash Flow MarginRevenue
$139.743m
+120.0%
1y CAGR+185.6%
3y CAGR+143.6%
5y CAGREarnings
-$79.992m
+78.8%
1y CAGR-17.1%
3y CAGR-7.3%
5y CAGREPS
-$0.81
+78.0%
1y CAGR-10.0%
3y CAGR-0.4%
5y CAGRBook Value
$1.238b
$1.481b
Assets$242.819m
Liabilities$293.882m
DebtDebt to Assets
19.8%
-3.9x
Debt to EBITDAFree Cash Flow
-$360.048m
-1.1%
1y CAGR-229.4%
3y CAGR-152.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company